Semaglutide 4.38 mg/mL Unit Dosing Calculation
For a semaglutide solution at 4.38 mg/mL, you must first identify which specific formulation you're using, as standard FDA-approved Ozempic contains 1.34 mg/mL, not 4.38 mg/mL 1. The concentration you've described does not match FDA-approved formulations and may represent a compounded preparation.
Standard FDA-Approved Dosing
The FDA-approved Ozempic pen contains 1.34 mg of semaglutide per mL 1. The pre-filled pen holds 1.5 mL total solution containing 2 mg semaglutide, delivering doses of:
- 0.25 mg (starting dose)
- 0.5 mg (escalation dose)
- 1 mg (maintenance dose)
- 2 mg (maximum dose for diabetes)
These are fixed doses delivered by the pen mechanism, not calculated in traditional "units" like insulin 1.
Critical Dosing Considerations
If Using Compounded Semaglutide at 4.38 mg/mL:
Volume calculation formula:
- Desired dose (mg) ÷ 4.38 mg/mL = Volume to inject (mL)
Example calculations:
- For 0.25 mg dose: 0.25 ÷ 4.38 = 0.057 mL (57 microliters)
- For 0.5 mg dose: 0.5 ÷ 4.38 = 0.114 mL (114 microliters)
- For 1 mg dose: 1 ÷ 4.38 = 0.228 mL (228 microliters)
- For 2.4 mg dose (obesity): 2.4 ÷ 4.38 = 0.548 mL
Dose Escalation Protocol
Start low and titrate slowly to minimize gastrointestinal adverse effects 2:
- Week 1-4: 0.25 mg weekly
- Week 5-8: 0.5 mg weekly
- Week 9+: 1 mg weekly (diabetes maintenance)
- For obesity: Continue escalating to 2.4 mg weekly over additional 4-week intervals
Never skip the escalation schedule—dose-dependent gastrointestinal side effects (nausea, vomiting, diarrhea) are significantly more common with rapid titration 2.
Critical Safety Warnings
Gastrointestinal Risks
- Delayed gastric emptying occurs with all GLP-1 receptor agonists 3
- Nausea and vomiting are the most common adverse effects, occurring in approximately 74% of patients at higher doses 4
- Management: Reduce meal size, avoid high-fat foods, limit alcohol and carbonated beverages 2
Perioperative Considerations
If surgery is planned, discontinue semaglutide 1 week before elective procedures due to delayed gastric emptying and aspiration risk 3. The long half-life of approximately 7 days necessitates this extended washout period 1.
Contraindications and Cautions
- Avoid in gastroparesis 2
- Use with caution in patients with history of pancreatitis 2
- No dose adjustment needed for renal or hepatic impairment 1, 5, 6
Common Pitfalls to Avoid
- Using non-FDA approved concentrations without proper verification—confirm your source and concentration before dosing
- Rapid dose escalation—always follow 4-week intervals between dose increases
- Inadequate patient education about gastrointestinal side effects—warn patients these are expected and typically improve
- Forgetting the long half-life—effects and side effects persist for approximately 1 week after discontinuation 1
- Confusing diabetes dosing (max 2 mg) with obesity dosing (2.4 mg)—verify indication
If you're using a 4.38 mg/mL concentration that differs from FDA-approved formulations, verify the source is legitimate and obtain specific dosing instructions from the compounding pharmacy, as this concentration requires precise measurement of very small volumes that may be prone to dosing errors.